# Vaccine and Treatment Evaluation Unit at Saint Louis University

> **NIH NIH UM1** · SAINT LOUIS UNIVERSITY · 2021 · $305,489

## Abstract

Saint Louis University (SLU) seeks to expand its service to the Vaccine and Treatment Evaluation Unit
(VTEU) network providing resources and expertise to help the network achieve its objectives of evaluating
vaccines, preventive biologics, therapeutics and diagnostics for infectious diseases. Dr. Daniel Hoft, SLU VTEU
PI, also serves as Co-PI for a VTEU Leadership Group (LG) application supported by all current VTEUs;
however, regardless of who leads the LG, SLU will provide full support to promote outstanding VTEU research.
Outstanding infrastructure for phase I-IV vaccine & therapeutic trials against priority pathogens: SLU has served
 as a VTEU for 29 years, conducted hundreds of phase I-IV trials in healthy and special populations of all ages,
 and can provide unique knowledge and extensive infrastructure to support VTEU network goals.
Diverse knowledge scientific skills for trial design priority areas: SLU investigators include experts in vaccinology,
 immunology, seasonal and pandemic influenza, tuberculosis, biodefense, urgent/emergent pandemic trials,
 liver/enteric diseases, sexually transmitted infections, malaria/neglected tropical diseases, epidemiology and
 arboviral diseases. We also provide state-of-the art multi-platform omics core expertise.
Urgent national preparedness trials: SLU has led urgent trials of vaccines against potential bioweapons
 (smallpox, anthrax, plague and tularemia), and emergent diseases (2009 H1N1 pandemic flu, avian H5 and H7
 flu and Zika/Yellow Fever). In addition to streamlined institutional review and contracting, SLU can contribute
 containment facilities for select agent work and inpatient human challenge.
Controlled Human Infection Models: SLU has developed the capacity for human challenge models to study
 influenza, parainfluenza, vaccinia, salmonella and tuberculosis immunity. We provide a 23-bed airborne
 containment facility for challenge studies with wild type GMP influenza strains, and have developed an active
 collaboration with SGS to standardize challenge protocols and obtain influenza challenge strains.
Expertise in First-in-Human, investigator-initiated and pharmacokinetic/pharmacodynamic studies: SLU has
 completed dozens of first-in-human and investigator-initiated trials of vaccines against influenza, tuberculosis,
 HCV, enteric pathogens, potential bioweapons and emerging flaviviruses. Experimental biology studies of
 mucosal and systemic immunity with human samples of blood, tissue and mucosal samples have identified
 biomarkers and targets for iterative influenza and tuberculosis vaccine development.
Sexually transmitted infection (STI) expertise: SLU's 10 years in the HIV Vaccine Trials Network provided SLU
 with expertise in STI. SLU also led a 44-site herpes vaccine efficacy trial (Herpevac), and two of the highest
 enrolling Herpevac sites have agreed to serve as Protocol-Specific Sites to expand our STI expertise. SLU ID
 follows ~450 HIV patients and closely collaborates with s...

## Key facts

- **NIH application ID:** 10447274
- **Project number:** 3UM1AI148685-02S6
- **Recipient organization:** SAINT LOUIS UNIVERSITY
- **Principal Investigator:** Daniel F. Hoft
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $305,489
- **Award type:** 3
- **Project period:** 2021-08-12 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10447274

## Citation

> US National Institutes of Health, RePORTER application 10447274, Vaccine and Treatment Evaluation Unit at Saint Louis University (3UM1AI148685-02S6). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10447274. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*